JP6012591B2 - β−ＮＧＦに対するアプタマー及びβ−ＮＧＦ介在疾患及び障害の治療におけるその使用 - Google Patents

β−ＮＧＦに対するアプタマー及びβ−ＮＧＦ介在疾患及び障害の治療におけるその使用 Download PDF

Info

Publication number
JP6012591B2
JP6012591B2 JP2013505029A JP2013505029A JP6012591B2 JP 6012591 B2 JP6012591 B2 JP 6012591B2 JP 2013505029 A JP2013505029 A JP 2013505029A JP 2013505029 A JP2013505029 A JP 2013505029A JP 6012591 B2 JP6012591 B2 JP 6012591B2
Authority
JP
Japan
Prior art keywords
ngf
aptamer
seq
sequence
aptamers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013505029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523177A (ja
Inventor
シュナイダー，ダニエル，ジェイ．
顕彦 久湊
顕彦 久湊
ウォー，シーラ
レズニコウ，ダニエル
昭 長袋
昭 長袋
恵秀 小野
恵秀 小野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Somalogic Inc
Original Assignee
Somalogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc filed Critical Somalogic Inc
Publication of JP2013523177A publication Critical patent/JP2013523177A/ja
Application granted granted Critical
Publication of JP6012591B2 publication Critical patent/JP6012591B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2013505029A 2010-04-12 2011-04-12 β−ＮＧＦに対するアプタマー及びβ−ＮＧＦ介在疾患及び障害の治療におけるその使用 Expired - Fee Related JP6012591B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32314510P 2010-04-12 2010-04-12
US61/323,145 2010-04-12
PCT/US2011/032017 WO2011130195A1 (en) 2010-04-12 2011-04-12 APTAMERS TO β-NGF AND THEIR USE IN TREATING β-NGF MEDIATED DISEASES AND DISORDERS

Publications (2)

Publication Number Publication Date
JP2013523177A JP2013523177A (ja) 2013-06-17
JP6012591B2 true JP6012591B2 (ja) 2016-10-26

Family

ID=44798979

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013505029A Expired - Fee Related JP6012591B2 (ja) 2010-04-12 2011-04-12 β−ＮＧＦに対するアプタマー及びβ−ＮＧＦ介在疾患及び障害の治療におけるその使用
JP2013505056A Active JP5901610B2 (ja) 2010-04-12 2011-04-12 ５位修飾ピリミジンとその使用
JP2016041782A Active JP6352324B2 (ja) 2010-04-12 2016-03-04 ５位修飾ピリミジンとその使用
JP2018034436A Active JP7025818B2 (ja) 2010-04-12 2018-02-28 ５位修飾ピリミジンとその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2013505056A Active JP5901610B2 (ja) 2010-04-12 2011-04-12 ５位修飾ピリミジンとその使用
JP2016041782A Active JP6352324B2 (ja) 2010-04-12 2016-03-04 ５位修飾ピリミジンとその使用
JP2018034436A Active JP7025818B2 (ja) 2010-04-12 2018-02-28 ５位修飾ピリミジンとその使用

Country Status (24)

Country Link
US (7) US8598140B2 (enExample)
EP (3) EP3345915B1 (enExample)
JP (4) JP6012591B2 (enExample)
KR (4) KR101952671B1 (enExample)
CN (4) CN102985435B (enExample)
AR (1) AR081452A1 (enExample)
AU (2) AU2011240774B2 (enExample)
BR (2) BR122021003805B8 (enExample)
CA (3) CA2793451A1 (enExample)
CO (1) CO6630139A2 (enExample)
DK (1) DK2558478T3 (enExample)
EA (1) EA022429B1 (enExample)
ES (3) ES2667491T3 (enExample)
HK (1) HK1201740A1 (enExample)
IL (5) IL222339A (enExample)
MX (4) MX2012011779A (enExample)
MY (1) MY160608A (enExample)
NO (1) NO2558478T3 (enExample)
NZ (1) NZ602618A (enExample)
PH (1) PH12012501838A1 (enExample)
SG (3) SG184089A1 (enExample)
TW (6) TWI505833B (enExample)
UA (1) UA105290C2 (enExample)
WO (2) WO2011130289A1 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5993279A (ja) * 1982-11-17 1984-05-29 富士通株式会社 ロボツトによるカ−ド，レシ−ト分離取出し方法
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US20110136099A1 (en) 2007-01-16 2011-06-09 Somalogic, Inc. Multiplexed Analyses of Test Samples
US8975026B2 (en) 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
US8404830B2 (en) * 2007-07-17 2013-03-26 Somalogic, Inc. Method for generating aptamers with improved off-rates
US8598140B2 (en) * 2010-04-12 2013-12-03 Somalogic, Inc. Aptamers to β-NGF and their use in treating β-NGF mediated diseases and disorders
CN103492569B (zh) 2010-11-05 2020-04-07 米拉根医疗公司 碱基经修饰的寡核苷酸
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
EP2646468B1 (en) 2010-12-01 2018-07-25 AlderBio Holdings LLC Anti-ngf compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
EP2831278B1 (en) * 2012-03-28 2019-05-08 Somalogic, Inc. Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions
HK1205764A1 (en) 2012-04-13 2015-12-24 Somalogic, Inc. Tuberculosis biomarkers and uses thereof
WO2014007438A1 (ko) * 2012-07-02 2014-01-09 국립대학법인 울산과학기술대학교 산학협력단 페리오스틴에 대한 압타머 및 이를 포함하는 항암제 조성물
EP2912182B1 (en) 2012-10-23 2021-12-08 Caris Science, Inc. Aptamers and uses thereof
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
US9939443B2 (en) 2012-12-19 2018-04-10 Caris Life Sciences Switzerland Holdings Gmbh Compositions and methods for aptamer screening
CA2902186C (en) 2013-03-14 2023-04-11 Somalogic, Inc. Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions
TWI594975B (zh) 2013-04-24 2017-08-11 第一三共股份有限公司 二羧酸化合物
WO2014177510A2 (en) * 2013-05-03 2014-11-06 Creabilis Sa Polymer conjugates of indolocarbazole compounds in the treatment of pruritus
GB201312295D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Suppression of itch
WO2015035305A1 (en) * 2013-09-09 2015-03-12 Somalogic, Inc. Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders
CA2924987C (en) * 2013-09-24 2022-08-16 Somalogic, Inc. Multiaptamer target detection
JP2015062364A (ja) * 2013-09-25 2015-04-09 Ｎｅｃソリューションイノベータ株式会社 クレンブテロールに結合する核酸分子およびその用途
JP2015062365A (ja) * 2013-09-25 2015-04-09 Ｎｅｃソリューションイノベータ株式会社 ラクトパミンに結合する核酸分子およびその用途
WO2015066001A1 (en) * 2013-10-29 2015-05-07 Albert Einstein College Of Medicine Of Yeshiva University Nucleic acid-scaffolded small molecule libraries
CN105658658B (zh) * 2013-11-21 2019-11-05 私募蛋白质体公司 胞苷-5-甲酰胺修饰的核苷酸组合物及其相关方法
RU2686992C2 (ru) * 2014-03-24 2019-05-06 Рибомик Инк. Аптамер для fgf2 и его применение
NO2718257T3 (enExample) * 2014-05-30 2018-04-14
KR102541110B1 (ko) 2014-08-25 2023-06-08 에이뮨 테라퓨틱스, 인코퍼레이티드 난 단백질 제형 및 이의 제조 방법
CN104561013A (zh) * 2015-01-05 2015-04-29 中国人民解放军南京军区福州总医院 基于高通量测序技术进行核酸适配体序列优化的方法
EP3414229B1 (en) 2016-02-09 2021-06-16 Pharmakea, Inc. Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof
MX2018011052A (es) * 2016-03-14 2019-01-24 Somalogic Inc Compuestos y metodos para la sintesis de fosforamidato de 5-(n-triptamina carboxamida protegida)-2'-desoxiuridina para ser incorporados en una secuencia nucleica.
CN107663220B (zh) * 2016-07-27 2020-10-02 上海伯豪医学检验所有限公司 修饰碱基、包含修饰碱基的核酸、适配体及其应用
WO2018079864A1 (ko) 2016-10-24 2018-05-03 김성천 TNF-α 결합 압타머 및 그것의 치료적 용도
EP4614155A3 (en) 2016-12-01 2025-10-15 Nautilus Subsidiary, Inc. Methods of assaying proteins
AU2018395430B2 (en) 2017-12-29 2024-05-23 Nautilus Subsidiary, Inc. Decoding approaches for protein identification
CN108299518A (zh) * 2018-02-02 2018-07-20 王成宇 一种2`-脱氧-β-尿苷的合成方法
WO2019154410A1 (zh) 2018-02-12 2019-08-15 翼高生物科技有限公司 针对骨硬化蛋白的适体及其用途
WO2019246289A1 (en) * 2018-06-22 2019-12-26 Somalogic, Inc. Improved proteomic multiplex assays
EP3942295A1 (en) 2019-03-22 2022-01-26 Somalogic, Inc. Reducing intersample analyte variability in complex biological matrices
AU2020278570A1 (en) 2019-05-17 2022-01-06 Somalogic Operating Co., Inc. Controlling intersample analyte variability in complex biological matrices
EP4165549A1 (en) 2020-06-11 2023-04-19 Nautilus Biotechnology, Inc. Methods and systems for computational decoding of biological, chemical, and physical entities
US12092642B2 (en) 2021-01-20 2024-09-17 Nautilus Subsidiary, Inc. Systems and methods for biomolecule quantitation
US20220227890A1 (en) 2021-01-21 2022-07-21 Nautilus Biotechnology, Inc. Systems and methods for biomolecule preparation
IL305336B2 (en) 2021-03-11 2025-09-01 Nautilus Subsidiary Inc Systems and methods for preserving biomolecules
WO2022199685A1 (zh) 2021-03-25 2022-09-29 安沛治疗有限公司 具有延长的体内半衰期的核酸分子缀合物
CN113481204B (zh) * 2021-07-02 2022-08-12 湖南赛奥维生物技术有限公司 一种蛋白的核酸适配体、其衍生物及其应用
EP4399528A1 (en) 2021-09-09 2024-07-17 Nautilus Subsidiary, Inc. Characterization and localization of protein modifications
EP4405683A1 (en) 2021-09-22 2024-07-31 Nautilus Subsidiary, Inc. Methods and systems for determining polypeptide interactions
JP2024535224A (ja) 2021-09-26 2024-09-30 アプタキュア セラピューティクス リミテッド Ｄｋｋ１に対するアプタマー及びその使用
US20230149883A1 (en) 2021-11-03 2023-05-18 Nautilus Biotechnology, Inc. Systems and methods for surface structuring
WO2023192917A1 (en) 2022-03-29 2023-10-05 Nautilus Subsidiary, Inc. Integrated arrays for single-analyte processes
US20230360732A1 (en) 2022-04-25 2023-11-09 Nautilus Subsidiary, Inc. Systems and methods for assessing and improving the quality of multiplex molecular assays
WO2023250364A1 (en) 2022-06-21 2023-12-28 Nautilus Subsidiary, Inc. Method for detecting analytes at sites of optically non-resolvable distances
WO2024059655A1 (en) 2022-09-15 2024-03-21 Nautilus Subsidiary, Inc. Characterizing accessibility of macromolecule structures
WO2024073599A1 (en) 2022-09-29 2024-04-04 Nautilus Subsidiary, Inc. Preparation of array surfaces for single-analyte processes
WO2024107857A1 (en) 2022-11-15 2024-05-23 Nautilus Subsidiary, Inc. Standard polypeptides
EP4630816A1 (en) 2022-12-09 2025-10-15 Nautilus Subsidiary, Inc. A method comprising performing on a single-analyte array at least 50 cycles of a process
EP4634285A1 (en) 2022-12-15 2025-10-22 Nautilus Subsidiary, Inc. Inhibition of photon phenomena on single molecule arrays
US20240241110A1 (en) 2023-01-12 2024-07-18 Nautilus Subsidiary, Inc. Characterization of glycans and glycoconjugates
WO2024206122A1 (en) 2023-03-24 2024-10-03 Nautilus Subsidiary, Inc. Improved transfer of nanoparticles to array surfaces
WO2024216233A1 (en) 2023-04-13 2024-10-17 Nautilus Subsidiary, Inc. Artificial proteins for displaying epitopes
WO2024228396A1 (ja) * 2023-05-01 2024-11-07 株式会社ナティアス オリゴヌクレオチド合成用の高脂溶性ヌクレオチドビルディングブロックおよびこれを用いたオリゴヌクレオチドの合成
US20240394902A1 (en) 2023-05-24 2024-11-28 Nautilus Subsidiary, Inc. Systems and methods for machine vision
WO2025128588A1 (en) 2023-12-11 2025-06-19 Nautilus Subsidiary, Inc. Methods and compositions of particle-based arrays
WO2025137166A1 (en) 2023-12-20 2025-06-26 Nautilus Subsidiary, Inc. Fluidic devices for single-analyte assays
WO2025199236A1 (en) 2024-03-22 2025-09-25 Nautilus Subsidiary, Inc. Plasmonic particle systems for single-analyte assays
US20250305034A1 (en) 2024-04-01 2025-10-02 Nautilus Subsidiary, Inc. Nanostructures for modulation of analyte conformation
CN119792485B (zh) * 2025-03-17 2025-06-24 温州医科大学附属口腔医院 一种抑菌促修复水凝胶敷料及制备方法

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267171A (en) 1979-07-02 1981-05-12 The Regents Of The University Of California C-5 Substituted cytosine nucleosides
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4594339A (en) 1982-04-06 1986-06-10 Sloan-Kettering Institute For Cancer Research Anti-herpes virus compositions containing 5-substituted 1-2'(deoxy-2-'-substituted-β-d-arabinofuranosyl)pyrimedene nucleosides
US5599720A (en) 1982-08-27 1997-02-04 Multilyte Limited Measurement of analyte concentration
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
DE3329892A1 (de) 1983-08-18 1985-03-07 Köster, Hubert, Prof. Dr., 2000 Hamburg Verfahren zur herstellung von oligonucleotiden
US4828979A (en) 1984-11-08 1989-05-09 Life Technologies, Inc. Nucleotide analogs for nucleic acid labeling and detection
US4737453A (en) 1984-12-12 1988-04-12 Immunomedics, Inc. Sandwich immunoassay utilizing a separation specific binding substance
AU4434585A (en) 1985-03-30 1986-10-23 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US5093232A (en) 1985-12-11 1992-03-03 Chiron Corporation Nucleic acid probes
US4752566A (en) 1985-12-17 1988-06-21 Genetics Institute, Inc. Displacement polynucleotide method and reagent complex employing labeled probe polynucleotide
US5047519A (en) 1986-07-02 1991-09-10 E. I. Du Pont De Nemours And Company Alkynylamino-nucleotides
US4997818A (en) 1987-09-21 1991-03-05 The University Hospital Therapeutic method for selectively treating terminal deoxynucleotidyl transferase-positive neoplastic leukemias and lymphomas
SE8802173D0 (sv) 1988-06-10 1988-06-10 Astra Ab Pyrimidine derivatives
KR920701230A (ko) * 1989-06-05 1992-08-11 원본미기재 엑소뉴클레아제-내성 올리고뉴클레오티드 및 그 제조방법
US5118672A (en) 1989-07-10 1992-06-02 University Of Georgia Research Foundation 5'-diphosphohexose nucleoside pharmaceutical compositions
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
EP0498843B1 (en) 1989-10-24 1996-06-12 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
ATE119541T1 (de) 1990-03-13 1995-03-15 Acic Canada Inc Verfahren zur herstellung von nucleosiden und ihre analogen.
WO1991014696A1 (en) 1990-03-29 1991-10-03 Gilead Sciences, Inc. Oligonucleotide-transport agent disulfide conjugates
US6346611B1 (en) 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5476766A (en) 1990-06-11 1995-12-19 Nexstar Pharmaceuticals, Inc. Ligands of thrombin
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5861254A (en) 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US6030776A (en) 1990-06-11 2000-02-29 Nexstar Pharmaceuticals, Inc. Parallel SELEX
DK0786469T3 (da) 1990-06-11 2006-07-10 Gilead Sciences Inc Nukleinsyreligander
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
EP0572529A4 (en) 1991-02-21 1994-11-02 Gilead Sciences Inc SPECIFIC APTAMER OF BIOMOLECULES AND PROCESS FOR PRODUCING THE SAME.
IE920561A1 (en) 1991-02-21 1992-08-26 Gilead Sciences Aptamer specific for thrombin and methods of use
US5840867A (en) * 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
EP1256589A3 (en) 1991-11-26 2003-09-17 Isis Pharmaceuticals, Inc. Oligomers containing modified pyrimidines
US5719273A (en) 1993-06-14 1998-02-17 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modifications methods using nucleophiles and carbon monoxide
US5580972A (en) 1993-06-14 1996-12-03 Nexstar Pharmaceuticals, Inc. Purine nucleoside modifications by palladium catalyzed methods
US5428149A (en) 1993-06-14 1995-06-27 Washington State University Research Foundation Method for palladium catalyzed carbon-carbon coulping and products
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
JP4899014B2 (ja) * 1995-06-02 2012-03-21 イーシー・テクノロジー・エルエルシー 求核試薬および一酸化炭素を用いるパラジウム触媒ヌクレオシド修飾方法
US5962225A (en) 1995-10-27 1999-10-05 Cygene, Inc. Methods and compositions for detection of specific nucleotide sequences
US5945527A (en) 1996-05-30 1999-08-31 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modification methods using nucleophiles and carbon monoxide
US6794499B2 (en) * 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US20060057573A1 (en) 2002-02-15 2006-03-16 Somalogic, Inc Methods and reagents for detecting target binding by nucleic acid ligands
US20070166741A1 (en) 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
US6020483A (en) 1998-09-25 2000-02-01 Nexstar Pharmaceuticals, Inc. Nucleoside modifications by palladium catalyzed methods
US6175001B1 (en) 1998-10-16 2001-01-16 The Scripps Research Institute Functionalized pyrimidine nucleosides and nucleotides and DNA's incorporating same
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
JP3485023B2 (ja) * 1999-05-20 2004-01-13 東亞合成株式会社 ヌクレオシド化合物
US20030054360A1 (en) * 1999-01-19 2003-03-20 Larry Gold Method and apparatus for the automated generation of nucleic acid ligands
KR100974917B1 (ko) * 2000-04-13 2010-08-09 파마셋 인코포레이티드 간염 바이러스 감염 치료를 위한 3'- 또는2'-하이드록시메틸 치환된 뉴클레오시드 유도체
US6376190B1 (en) 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
US20030148335A1 (en) 2001-10-10 2003-08-07 Li Shen Detecting targets by unique identifier nucleotide tags
EP1489171B1 (en) 2002-03-19 2012-10-31 Fujitsu Limited Functional molecule and process for producing the same
US7767803B2 (en) 2002-06-18 2010-08-03 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
CA2407825A1 (en) 2002-10-11 2004-04-11 Andrew J. Simmonds Trap-tagging: a novel method for the identification and purification of rna-protein complexes
AU2004204456A1 (en) 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
JP4119976B2 (ja) * 2003-02-07 2008-07-16 国立大学法人群馬大学 ５位置換ピリミジンデオキシヌクレオチド誘導体、及びそれを用いた核酸の合成方法
WO2005024042A2 (en) 2003-09-04 2005-03-17 The Regents Of The University Of California Aptamers and methods for their in vitro selection and uses thereof
US20050227225A1 (en) 2004-04-07 2005-10-13 Roche Molecular Systems, Inc. Stabilization of biomolecules in samples
CA2562151C (en) 2004-04-30 2016-09-06 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a c5-modified pyrimidine
JP2006117542A (ja) * 2004-10-19 2006-05-11 Pias Arise Kk 神経成長因子産生抑制剤、並びにその神経成長因子産生抑制剤を配合した皮膚外用剤、化粧料、医薬部外品、痒み予防及び治療剤、及びアトピー性皮膚炎治療剤
EP1828217A2 (en) 2004-12-16 2007-09-05 Febit Biotech GmbH Polymerase-independent analysis of the sequence of polynucleotides
WO2007044427A2 (en) 2005-10-05 2007-04-19 Panomics, Inc. Detection of nucleic acids from whole blood
JP5256578B2 (ja) * 2005-12-20 2013-08-07 大正製薬株式会社 掻痒性皮膚疾患の予防または治療剤
TWI507528B (zh) 2006-01-17 2015-11-11 Somalogic Inc 測試樣品的多重分析方法
EP1996193A2 (en) 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
EP1897886A1 (en) * 2006-09-08 2008-03-12 Bayer Schering Pharma Aktiengesellschaft Compounds as aptamer-dimers and their uses in diagnosis and therapy
US8242258B2 (en) * 2006-12-03 2012-08-14 Agilent Technologies, Inc. Protecting groups for RNA synthesis
CA2673029C (en) 2006-12-22 2017-03-28 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US8975026B2 (en) 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
US20110136099A1 (en) 2007-01-16 2011-06-09 Somalogic, Inc. Multiplexed Analyses of Test Samples
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
EP2144921A2 (en) * 2007-02-27 2010-01-20 K.U. Leuven Research and Development Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents
US20090137506A1 (en) * 2007-05-02 2009-05-28 Sirna Therapeutics, Inc. RNA Interference Mediated Inhibition of Cyclic Nucleotide Type 4 Phosphodiesterase (PDE4B) Gene Expression Using Short Interfering Nucleic Acid (siNA)
MX344253B (es) 2007-07-17 2016-12-09 Somalogic Inc Metodo para generar aptameros con constantes de disociacion mejoradas.
US8404830B2 (en) 2007-07-17 2013-03-26 Somalogic, Inc. Method for generating aptamers with improved off-rates
US20090215050A1 (en) 2008-02-22 2009-08-27 Robert Delmar Jenison Systems and methods for point-of-care amplification and detection of polynucleotides
US8703416B2 (en) 2008-07-17 2014-04-22 Somalogic, Inc. Method for purification and identification of sperm cells
JP5602020B2 (ja) * 2008-09-24 2014-10-08 株式会社リボミック Ｎｇｆに対するアプタマー及びその使用
US20120322862A1 (en) 2010-03-03 2012-12-20 Somalogic, Inc. Aptamers to 4-1BB and Their Use in Treating Diseases and Disorders
WO2011119852A1 (en) 2010-03-24 2011-09-29 Rxi Pharmaceuticals Corporation Reduced size self-delivering rnai compounds
US9175292B2 (en) 2010-03-24 2015-11-03 Fujimoto Pharmaceutical Corporation Aptamer for NGF and use thereof
US8598140B2 (en) 2010-04-12 2013-12-03 Somalogic, Inc. Aptamers to β-NGF and their use in treating β-NGF mediated diseases and disorders
WO2011130065A1 (en) 2010-04-12 2011-10-20 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF MET GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CN103492569B (zh) * 2010-11-05 2020-04-07 米拉根医疗公司 碱基经修饰的寡核苷酸
EP2831278B1 (en) * 2012-03-28 2019-05-08 Somalogic, Inc. Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions
CN105658658B (zh) 2013-11-21 2019-11-05 私募蛋白质体公司 胞苷-5-甲酰胺修饰的核苷酸组合物及其相关方法

Also Published As

Publication number Publication date
IL256013B (en) 2018-05-31
US20150376223A1 (en) 2015-12-31
SG2014006522A (en) 2014-03-28
US20180127450A1 (en) 2018-05-10
TWI671309B (zh) 2019-09-11
CA2793451A1 (en) 2011-10-20
IL252703A (en) 2017-12-31
AU2011240677B2 (en) 2015-05-14
KR101842269B1 (ko) 2018-03-26
JP2016145230A (ja) 2016-08-12
AU2011240774B2 (en) 2014-04-10
KR20180030229A (ko) 2018-03-21
MX2012011771A (es) 2012-12-17
CN102985435A (zh) 2013-03-20
BR112012025872B1 (pt) 2021-04-20
US10221207B2 (en) 2019-03-05
KR102185779B1 (ko) 2020-12-03
ES2667491T3 (es) 2018-05-11
JP2013523887A (ja) 2013-06-17
SG184497A1 (en) 2012-11-29
HK1252803A1 (en) 2019-06-06
KR101952671B1 (ko) 2019-02-27
IL222339A (en) 2015-11-30
CN104069512A (zh) 2014-10-01
US20160355540A1 (en) 2016-12-08
WO2011130289A1 (en) 2011-10-20
IL252703A0 (en) 2017-08-31
CA3066785A1 (en) 2011-10-20
MX373860B (es) 2020-03-25
MX2012011779A (es) 2012-12-17
EP2558478B1 (en) 2018-03-07
CA2797188C (en) 2020-03-31
TW201900668A (zh) 2019-01-01
CN102858990A (zh) 2013-01-02
CA2797188A1 (en) 2011-10-20
TWI684596B (zh) 2020-02-11
US20110275794A1 (en) 2011-11-10
EP3345915A1 (en) 2018-07-11
BR122021003805B8 (pt) 2022-10-25
TW201629079A (zh) 2016-08-16
EA201291034A1 (ru) 2013-04-30
ES2905656T3 (es) 2022-04-11
MX2020003168A (es) 2022-05-31
BR122021003805B1 (pt) 2021-10-13
PH12012501838A1 (en) 2013-02-04
AR081452A1 (es) 2012-09-05
DK2558478T3 (en) 2018-05-22
KR20130043099A (ko) 2013-04-29
MX392756B (es) 2025-03-24
KR20190018750A (ko) 2019-02-25
EA022429B1 (ru) 2015-12-30
IL256013A (en) 2018-01-31
BR112012025872B8 (pt) 2021-05-25
NO2558478T3 (enExample) 2018-08-04
CN107033204A (zh) 2017-08-11
AU2011240774A1 (en) 2012-10-18
IL222339A0 (en) 2012-12-31
US20140058076A1 (en) 2014-02-27
TWI593701B (zh) 2017-08-01
IL256014B (en) 2018-05-31
UA105290C2 (ru) 2014-04-25
SG184089A1 (en) 2012-11-29
US9163056B2 (en) 2015-10-20
JP2013523177A (ja) 2013-06-17
CN102858990B (zh) 2016-08-03
CN102985435B (zh) 2016-10-26
HK1201740A1 (en) 2015-09-11
TW201134482A (en) 2011-10-16
TWI505833B (zh) 2015-11-01
EP2558478A1 (en) 2013-02-20
WO2011130195A1 (en) 2011-10-20
MY160608A (en) 2017-03-15
NZ602618A (en) 2013-12-20
IL256014A (en) 2018-01-31
IL242038A (en) 2017-07-31
JP5901610B2 (ja) 2016-04-13
TW201730198A (zh) 2017-09-01
JP7025818B2 (ja) 2022-02-25
EP2558586A1 (en) 2013-02-20
ES2610159T3 (es) 2017-04-26
US20130012693A1 (en) 2013-01-10
US8598140B2 (en) 2013-12-03
US20190233461A1 (en) 2019-08-01
BR112012025872A2 (pt) 2016-10-18
IL242038A0 (en) 2015-11-30
JP2018109050A (ja) 2018-07-12
EP2558586B1 (en) 2016-10-12
EP2558586A4 (en) 2014-10-15
KR20130103317A (ko) 2013-09-23
CO6630139A2 (es) 2013-03-01
EP3345915B1 (en) 2021-11-24
TW202019943A (zh) 2020-06-01
TWI643864B (zh) 2018-12-11
EP2558478A4 (en) 2013-10-23
JP6352324B2 (ja) 2018-07-04
AU2011240677A1 (en) 2012-11-01
TW201936623A (zh) 2019-09-16

Similar Documents

Publication Publication Date Title
JP6012591B2 (ja) β−ＮＧＦに対するアプタマー及びβ−ＮＧＦ介在疾患及び障害の治療におけるその使用
JP2019500349A (ja) 中枢神経系疾患の処置のための組成物および方法
JP2023504195A (ja) 状態および疾患の処置のためのアンチセンスオリゴマー
CN109439664A (zh) 结合il-6的适体及其在治疗或诊断il-6介导的疾患中的用途
CN119790152A (zh) 使用unc13a基因转录本的调节剂治疗神经系统疾病
IL313205A (en) Microbial symbiosis between a fungus and an alga
JP2022537581A (ja) Ｐｐｍ１阻害剤およびその使用方法
US9993522B2 (en) Treatment of pain by inhibition of USP5 de-ubiquitinase
CN113490739A (zh) 通过磷酸二酯酶4(pde4)抑制治疗癫痫的方法
KR20250155076A (ko) 안티센스 올리고머 제형
HK1180368A (en) APTAMERS TO β-NGF AND THEIR USE IN TREATING β-NGF MEDIATED DISEASES AND DISORDERS
US20250066781A1 (en) Methods for treating conditions and diseases
WO2025252669A1 (en) Modified oligonucleotides for reducing atxn3 expression
WO2022158608A1 (ja) 良性成人型家族性ミオクローヌスてんかんの予防又は治療剤
WO2025199503A1 (en) Methods for treating conditions and diseases
WO2023107531A2 (en) Antisense oligonucleotide drug targets
HK40029701B (zh) 天使综合征反义治疗
HK1262959B (en) Compositions and methods for treatment of central nervous system diseases
HK1262959A1 (en) Compositions and methods for treatment of central nervous system diseases

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150811

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160614

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160706

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160823

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160920

R150 Certificate of patent or registration of utility model

Ref document number: 6012591

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees